SCHEMBL2152700

SCHEMBL2152700

COc1cc2c(Cl)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 9/20 0.64
EHMT1 Q9H9B1 9/20 0.64
AXL P30530 5/20 0.56
EGFR P00533 3/20 0.56
WEE2 P0C1S8 2/20 0.56
WEE1 P30291 2/20 0.56
PKMYT1 Q99640 2/20 0.56
KDR P35968 2/20 0.56
FGFR1 P11362 1/20 0.56
FLT1 P17948 1/20 0.56
FLT4 P35916 1/20 0.56
FYN P06241 2/20 0.56
SRC P12931 2/20 0.56
CSF1R P07333 3/20 0.55
STK25 O00506 1/20 0.55
CIT O14578 1/20 0.55
RIOK3 O14730 1/20 0.55
MAP2K7 O14733 1/20 0.55
CHEK1 O14757 1/20 0.55
CASK O14936 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27006970 0.94 EGFR (0.59) EHMT2EHMT1AXLEGFRWEE2
SCHEMBL29636829 0.92 EHMT2 (0.76) EHMT2EHMT1EGFRKDRFGFR1
SCHEMBL8526894 0.92 EHMT2 (0.76) EHMT2EHMT1EGFRKDRFGFR1
Hydrochloric Acid SCHEMBL6433786 0.91 EHMT2 (0.74) EHMT2EHMT1EGFRKDRFGFR1
SCHEMBL2748129 0.91 EHMT2 (0.74) EHMT2EHMT1EGFRKDRSRC
SCHEMBL5097860 0.89 EGFR (0.64) EHMT2EHMT1AXLEGFRKDR
SCHEMBL903068 0.89 EGFR (0.64) EHMT2EHMT1AXLEGFRKDR
SCHEMBL2152791 0.89 EHMT2 (0.62) EHMT2EHMT1EGFRSRCERBB2
Hydrochloric Acid SCHEMBL6432089 0.88 EGFR (0.62) EHMT2EHMT1AXLEGFRKDR
SCHEMBL2746706 0.86 EHMT2 (0.67) EHMT2EHMT1EGFRKDRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314232-B2 Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide GLAXOSMITHKLINE LLC (US) 2012-11-20 US disclosed
EP-2339918-A1 PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE GlaxoSmithKline LLC (US) 2011-07-06 EP disclosed
US-20100081805-A1 Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide EXELIXIS, INC. 2010-04-01 US disclosed
WO-2010036831-A1 PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE GLAXOSMITHKLINE LLC (US) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081805-A1 Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide QDPR, CBR3, NQO2 EHMT2 3821/4885EHMT1 4297/4885AXL 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.